Advancing patient care


Committed to developing and commercializing neurology, orphan, and specialty therapies

Assertio Therapeutics is committed to providing responsible solutions to advance patient care in the Company’s core areas of neurology, orphan and specialty medicines. Assertio continues to identify, license and develop new products that offer enhanced options for patients that may be underserved by existing therapies.

Assertio pipeline products

Product Potential Indication Phase 1/2P 1/2 Phase 3P 3 SubmittedS ApprovedA
Diclofenac Potassium Mild/moderate acute pain 12-17 years X X X O
Long-acting Cosyntropin Diagnosis of Adrenal Insufficiency X X X O
Diclofenac potassium (Liquid Formulation) Acute Migraine Attacks X O O O
S = Submitted | A = Approved

Assertio Therapeutic’s authorized distributers can be found here.